New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 30, 2014
06:10 EDTSGYPSynergy Pharmaceuticals' plecanatide shows positive results in Phase 2B study
Synergy Pharmaceuticals announced positive top-line results from a phase 2b dose-ranging study assessing plecanatide’s safety and efficacy in 424 patients with irritable bowel syndrome with constipation. The primary objective of this trial was to determine an effective, safe and well tolerated dose for plecanatide phase 3 trials with IBS-C patients. Plecanatide demonstrated statistically significant improvement in complete spontaneous bowel movement frequency – the study’s primary endpoint – and was safe and well tolerated. The most common event was diarrhea, which occurred in 9.3% of the 3.0mg plecanatide-treated patients. The company intends to initiate pivotal phase 3 trials in IBS-C patients in 2H14.
News For SGYP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2015
10:25 EDTSGYPOptions with decreasing implied volatility
Subscribe for More Information
November 16, 2015
16:53 EDTSGYPPaulson reduced stake in Valeant
Paulson & Co. gave a quarterly update on its stakes in a filing this afternoon. NEW STAKES: Perrigo (PRGO), CIT Group (CIT), Precision Castparts (PCP), Cameron (CAM), and Altera (ALTR). INCREASED STAKES: Teva (TEVA), Post Holdings (POST), Starwood Hotels (HOT), LivaNova (LIVN), and Synergy Pharmaceuticals (SGYP). DECREASED STAKES: Valeant (VRX), Shire (SHPG), Whiting Petroleum (WLL), Computer Sciences (CSC), and Oasis Petroleum (OAS). LIQUIDATED STAKES: Houghton Mifflin Harcourt (HMHC), Broadcom (BRCM), and Sprint (S).
06:01 EDTSGYPSynergy Pharmaceuticals appoints Gary Sender as CFO
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use